Nicox AAQS 2025

Što radi Nicox?

Nicox SA is a French pharmaceutical company specializing in the development and commercialization of innovative therapy systems for eye diseases. It was founded in 1996 as a spin-off of Nestlé's research activities in the field of ophthalmology. The company's business model is based on the development of drugs based on nitric oxide (NO), a gaseous molecule that plays an important role in regulating blood flow and inflammation processes in the human body. Nicox SA's technology allows for the targeted release of NO donors in specific areas of the eye to reduce disease-related inflammation and damage. This provides a promising alternative to conventional therapies for a range of eye diseases. Nicox SA is divided into three business areas: Ophthalmology, Diagnostics, and Contracts. In the Ophthalmology segment, the company focuses on the development of drugs for the treatment of glaucoma, dry eye, and other eye diseases. Important products in this area include Vyzulta, a combination of an NO donor and a glaucoma drug, as well as NCX 470, an NO donor for the treatment of glaucoma. In addition, the company is working on the development of NCX 4251, an NO donor for the treatment of blepharitis, an inflammation of the eyelids. In the Diagnostics segment, Nicox SA offers innovative diagnostic tests for ophthalmology based on tear fluid analysis. These tests enable ophthalmologists to diagnose and monitor certain eye diseases more quickly and accurately. Key products in this area include AdenoPlus, a rapid test for diagnosing adenovirus conjunctivitis, and ClearSight, a test for monitoring glaucoma patients. The Contracts segment offers customized clinical research services for customers in the pharmaceutical industry. This segment is an important part of Nicox SA's strategy to generate additional revenue and finance the development of new therapies. Overall, Nicox SA has a strong pipeline of new therapies and diagnostic tests that allow the company to consolidate its position as a leading provider of eye medications. The company works closely with its industry and academic research partners to develop and bring innovative therapies to the market. In summary, Nicox SA is an innovative and rapidly growing company focusing on the development and commercialization of therapies for eye diseases. The company has a strong pipeline of new products and services and collaborates closely with its partners to strengthen its position in the industry. Nicox ist eines der beliebtesten Unternehmen auf Eulerpool.com.